Skip to content

Niel3D Marketplace

Menu
  • politics
  • general
  • entertainment
  • sports
  • technology
  • business
  • News
  • international relations
  • culture
  • law
Menu

This new blood pressure drug could treat disease more effectively

Posted on 2025 年 11 月 2 日 by admin

A new blood pressure medicine called **lorundrostat** is showing real promise for people who struggle to control their high blood pressure. A recent clinical trial presented at the American College of Cardiology’s Annual Scientific Session (ACC.25) found that this new drug could effectively lower blood pressure in individuals whose condition has not been well managed with current medications.

### Understanding High Blood Pressure

High blood pressure, or hypertension, is a major cause of heart attacks, strokes, and heart failure. In the U.S., more than two out of three people with high blood pressure don’t have it under control. Some do not receive treatment, while others find that the medicines they take don’t work well enough.

### What is Lorundrostat?

Lorundrostat belongs to a new group of medications called **aldosterone synthase inhibitors (ASIs)**. Most blood pressure drugs block aldosterone after it’s been produced, but lorundrostat works differently by stopping the body from making too much of this hormone in the first place. Aldosterone causes the body to retain salt and water, which leads to increased blood pressure.

### The ADVANCE-HTN Phase 2b Trial

Researchers tested lorundrostat on 285 participants from 103 locations across the U.S. These individuals were already taking two to five different blood pressure medications, yet their hypertension remained uncontrolled. The average age of participants was 60, and 40% were women. Notably, over half of the participants were Black — a vital inclusion since Black Americans often face higher rates of uncontrolled hypertension and are underrepresented in clinical trials.

The study began with all participants following the same basic blood pressure treatments for three weeks. Those whose blood pressure remained high were then randomly assigned to one of three groups:

– **Placebo group:** received a pill with no active medicine
– **50 mg lorundrostat group:** received 50 mg of lorundrostat daily
– **50-100 mg lorundrostat group:** started with 50 mg daily, with the option to increase to 100 mg after four weeks

### Study Results

After 12 weeks, the results were clear:

– The 50 mg lorundrostat group experienced a 24-hour average blood pressure drop of **15.4 mm Hg**.
– The 50-100 mg group saw a drop of **13.9 mm Hg**.
– The placebo group had a smaller reduction of only **7.4 mm Hg**.

This means lorundrostat lowered blood pressure by about 7 to 8 mm Hg more than the placebo.

Even more encouraging, **42%** of people in the lorundrostat group achieved blood pressure control by week 4, compared to just **19%** of those in the placebo group. Importantly, the drug worked equally well across different racial groups.

### Safety and Side Effects

Dr. Luke Laffin from the Cleveland Clinic, who led the study, reported that lorundrostat was generally well tolerated. The main side effects were similar to those seen with other drugs affecting aldosterone, including slightly elevated potassium levels and some changes in kidney function. Overall, most participants handled the medication without serious issues.

### What’s Next?

This trial was funded by Mineralys Therapeutics, the company developing lorundrostat. A larger study is already underway to further evaluate the drug’s safety and long-term effects.

For people with high blood pressure that hasn’t improved despite current medications, lorundrostat could represent a significant advancement. Its unique way of working offers new hope — especially for groups like Black Americans, who are at higher risk of complications from hypertension.

If future studies confirm these findings, lorundrostat might soon become a valuable new option to help more people get their blood pressure under control and reduce their risk of strokes, heart attacks, and other serious health problems.

—

### Additional Resources

If you care about blood pressure management, consider reading more about:

– Common blood pressure medications that may extend your healthy lifespan
– A common high blood pressure drug linked to sudden cardiac arrest
– Why timing matters when taking high blood pressure pills
– How 1 in 5 people with high blood pressure taking medication may inadvertently worsen their condition

Stay informed and proactive about your heart health!
https://knowridge.com/2025/11/this-new-blood-pressure-drug-could-treat-disease-more-effectively/

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RSS The New York Times

  • Deported and Desperate to Be Reunited With Their Children 2025 年 11 月 25 日 Luis Ferré-Sadurní, Julie Turkewitz and Isayen Herrera
  • Challengers Take on N.Y. House Democrats, Targeting Their Ties to Israel 2025 年 11 月 25 日 Benjamin Oreskes
  • 100 Notable Books of 2025 2025 年 11 月 25 日 The New York Times Books Staff
  • U.S. Army Secretary Meets With Russian Envoys on Ukraine Peace Plan 2025 年 11 月 25 日 Helene Cooper
  • Ritz-Carlton Is Sued Over Luxury Safari Camp in Kenya 2025 年 11 月 25 日 Tariro Mzezewa
  • Russia Bombards Kyiv Even as Ukraine Claims Progress in Peace Talks 2025 年 11 月 25 日 Maria Varenikova
  • Warmed by Japan’s Support, Taiwan Takes Up Sushi Diplomacy 2025 年 11 月 25 日 Lily Kuo and Pei-Lin Wu
  • China and Japan, With Trump in the Middle, Are in a Showdown 2025 年 11 月 25 日 Keith Bradsher and River Akira Davis
  • Mamdani Response to Protest Inflames Tensions With Jewish Leaders 2025 年 11 月 25 日 Dana Rubinstein and Liam Stack
  • Trump Administration Is Taking Billions in Stakes in Firms Like Intel 2025 年 11 月 25 日 Ana Swanson
  • I’m a Professor. A.I. Has Changed My Classroom, but Not for the Worse. 2025 年 11 月 25 日 Carlo Rotella
  • How Rubio Tried to Bring a Pro-Russia Peace Plan to Middle Ground 2025 年 11 月 25 日 David E. Sanger, Zolan Kanno-Youngs and Edward Wong
  • As Trump Pushes to End Ukraine War, Europe Toils to Have a Say 2025 年 11 月 25 日 Michael D. Shear
  • Faux Jewels and Slimming Belts: Why Shopping on TikTok Is a Lot Like QVC 2025 年 11 月 25 日 Emmett Lindner
  • Budget Will Be a Big Test for the UK’s Most Unpopular Chancellor in Decades 2025 年 11 月 25 日 Eshe Nelson

近期文章

  • The UK Already Has Quite a Few Wealth Taxes
  • Harry Dunmire named Wiregrass Tech Student of the Year
  • Residential societies join schools in organising theatre visits for 120 Bahadur
  • Elon Musk backs xAI’s Grok 5 to defeat top League of Legends players by 2026
  • “When you want to rely on KL Rahul, that’s the time he disappoints” – Former India selector’s massive take on batter amid IND vs SA 2025 Tests

近期评论

No comments to show.
© 2025 Niel3D Marketplace | Powered by Superbs Personal Blog theme
友情链接
Telegram中文版官网 | 爱思助手 | 旺商聊 | zip解压软件 | Telegram中文版官网 | 搜狗输入法下载 | 向日葵官网 | 雷电模拟器 | LINE下载 | 丝瓜聊天